Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

27 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Emerging immunotherapy in pediatric lymphoma.
Erker C, Harker-Murray P, Burke MJ. Erker C, et al. Future Oncol. 2016 Jan;12(2):257-70. doi: 10.2217/fon.15.282. Epub 2015 Nov 30. Future Oncol. 2016. PMID: 26616565 Review.
Children's Oncology Group Trial AALL1231: A Phase III Clinical Trial Testing Bortezomib in Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia and Lymphoma.
Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, Annett RD, Archer JH, Asselin BL, August KJ, Cho SY, Dunsmore KP, Fisher BT, Freedman JL, Galardy PJ, Harker-Murray P, Horton TM, Jaju AI, Lam A, Messinger YH, Miles RR, Okada M, Patel SI, Schafer ES, Schechter T, Singh N, Steele AC, Sulis ML, Vargas SL, Winter SS, Wood C, Zweidler-McKay P, Bollard CM, Loh ML, Hunger SP, Raetz EA. Teachey DT, et al. Among authors: harker murray p. J Clin Oncol. 2022 Jul 1;40(19):2106-2118. doi: 10.1200/JCO.21.02678. Epub 2022 Mar 10. J Clin Oncol. 2022. PMID: 35271306 Free PMC article. Clinical Trial.
Editorial: Non-cellular immunotherapies in pediatric malignancies.
Alexander S, Harker-Murray P, Hayashi RJ. Alexander S, et al. Among authors: harker murray p. Front Immunol. 2024 Feb 21;15:1379278. doi: 10.3389/fimmu.2024.1379278. eCollection 2024. Front Immunol. 2024. PMID: 38449864 Free PMC article. No abstract available.
A dose substitution of anthracycline intensity with dose-dense rituximab in children and adolescents with good-risk mature B-cell lymphoma.
Goldman S, Barth M, Shiramizu B, Shi Q, Hochberg J, Klejmont L, Harrison L, Basso J, Chu Y, Islam H, Gerard P, Agsalda-Garcia M, Shieh T, Oesterheld J, Heym K, Kirov I, Drachtman R, Harker-Murray P, Perkins S, Miles RR, Cairo M. Goldman S, et al. Leukemia. 2021 Oct;35(10):2994-2997. doi: 10.1038/s41375-021-01256-8. Epub 2021 May 3. Leukemia. 2021. PMID: 33941850 No abstract available.
Nivolumab and brentuximab vedotin with or without bendamustine for R/R Hodgkin lymphoma in children, adolescents, and young adults.
Harker-Murray P, Mauz-Körholz C, Leblanc T, Mascarin M, Michel G, Cooper S, Beishuizen A, Leger KJ, Amoroso L, Buffardi S, Rigaud C, Hoppe BS, Lisano J, Francis S, Sacchi M, Cole PD, Drachtman RA, Kelly KM, Daw S. Harker-Murray P, et al. Blood. 2023 Apr 27;141(17):2075-2084. doi: 10.1182/blood.2022017118. Blood. 2023. PMID: 36564047 Free PMC article. Clinical Trial.
27 results